SECUKINUMAB 150MG

Secukinumab belongs to monoclonal antibody which is a protein which

recognises and connect to an inflammatory protein called Interleukin 17A
(IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the
body’s immune system produces an increased amount of IL-17A which
causes the symptoms such as swollen and painful joint. Scapho is a
prescription drugs which is used under proper guidance of medical
oncologist

INDICATION

Scapho indicated for the treatment of following condition

Plaque Psoriasis
Psoriatic arthritis
Ankylosing spondylitis.
DOSAGE

Plaque Psoriasis:
Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
For some patientsmay be acceptable containing dose of 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Recommended dosage
Psoriatic arthritis for other patients, administer with or without a loading dosage by
SC injection
Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and
q4wk thereafter
Scapho without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Ankylosing Spondylitis:
Given with or without a loading dosage by SC injection
Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and
q4wk thereafter
Scapho without a loading dose is administrated150 mg SC q4wk
MECHANISM

Secukinumab mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine

(messenger protein) contains in the development of psoriasis and is found in peak
concentrations in psoriasis plaques.
Secukinumab consist of human IgG1 monoclonal antibody which selectively binds to
IL-17A, rapidly prohibiting its pro-inflammatory effects.
ADME

Maximum plasma concentration for single dose is 6 days and weekly dosing for first
month is 31-34 days
Volume of distribution is 7.1 – 8.6 (IV administration)
The drug scapho is Metabolized via intracellular catabolism.
Scapho has half-life is 22-31 days
PRECAUTION

Scapho may have high risk of infections; use with caution in patients with chronic
infection or a history of recurrent infection
Before to initiation of scapho,start with anti-TB therapy in patients with a history of
latent or active TB in whom an adequate course of treatment cannot be confirmed
May infuriate Crohn disease
Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho
immediately and start anaphylaxis treatment
DRUG INTERACTION

Live vaccinations combination with scapho should be avoided

CYP450 substrates concomitant use with scapho injection may altered by increased
levels of certain cytokines.
CONTRAINDICATION

Patients having Serious hypersensitivity reactions to the active substance or to any of

the excipients
STORAGE

Store the drug at 2℃ to 8℃.

MISSED DOSE

In case of missed dose, patients must consult with medical practitioner and follow the
instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule.

SIDE EFFECTS

• Infections
• Nasopharyngitis
• Diarrhea
• URT infection
• Rhinitis
• Oral herpes
• Pharyngitis
• Urticaria
• Rhinorrhoea